NO963064L - Behandling av normotensive glaukoma med angiotensin-II-antagonister - Google Patents

Behandling av normotensive glaukoma med angiotensin-II-antagonister

Info

Publication number
NO963064L
NO963064L NO963064A NO963064A NO963064L NO 963064 L NO963064 L NO 963064L NO 963064 A NO963064 A NO 963064A NO 963064 A NO963064 A NO 963064A NO 963064 L NO963064 L NO 963064L
Authority
NO
Norway
Prior art keywords
pct
treatment
angiotensin
antagonists
sec
Prior art date
Application number
NO963064A
Other languages
English (en)
Other versions
NO963064D0 (no
Inventor
Alicia Huxley
Georg Mathis
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO963064D0 publication Critical patent/NO963064D0/no
Publication of NO963064L publication Critical patent/NO963064L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Anvendelsen av en anglotensin-II-antagonist eller et farmasøytisk akseptabelt salt derav ved fremstilling av et farmasøytisk preparat for behandling av normal- trykk-glaukom og neurodegenerative prosesser.
NO963064A 1994-02-08 1996-07-23 Behandling av normotensive glaukoma med angiotensin-II-antagonister NO963064L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810071 1994-02-08
PCT/IB1995/000056 WO1995021609A1 (en) 1994-02-08 1995-01-26 Treatment of normotensive glaucoma with angiotensin ii antagonists

Publications (2)

Publication Number Publication Date
NO963064D0 NO963064D0 (no) 1996-07-23
NO963064L true NO963064L (no) 1996-07-23

Family

ID=8218203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963064A NO963064L (no) 1994-02-08 1996-07-23 Behandling av normotensive glaukoma med angiotensin-II-antagonister

Country Status (17)

Country Link
US (1) US5889020A (no)
EP (1) EP0743852B1 (no)
JP (1) JPH09508641A (no)
CN (1) CN1140409A (no)
AT (1) ATE300287T1 (no)
AU (1) AU1423795A (no)
CA (1) CA2181461A1 (no)
CY (1) CY2567B1 (no)
DE (1) DE69534339T2 (no)
DK (1) DK0743852T3 (no)
ES (1) ES2243933T3 (no)
FI (1) FI963083A (no)
IL (1) IL112520A0 (no)
MX (1) MX9603259A (no)
NO (1) NO963064L (no)
WO (1) WO1995021609A1 (no)
ZA (1) ZA95958B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
NZ282485A (en) * 1994-03-16 1997-06-24 Sankyo Co Treatment of ocular hypertension using imidazole derivatives
JPH10167961A (ja) * 1996-12-11 1998-06-23 Santen Pharmaceut Co Ltd 緑内障治療剤
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
CN1234357C (zh) * 1998-07-10 2006-01-04 诺瓦提斯公司 缬沙坦和钙通道阻断剂的抗超敏组合
WO2000066161A1 (fr) * 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
WO2000076543A1 (fr) * 1999-06-11 2000-12-21 Sankyo Company, Limited Composition permettant de reduire la tension oculaire et destinee a l'administration topique
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
WO2001030388A1 (fr) * 1999-10-25 2001-05-03 Senju Pharmaceutical Co., Ltd. Agents permettant de soulager la tension d'un muscle ciliaire
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
WO2001060362A1 (en) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. TNF-α INHIBITORS
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
TWI349549B (en) * 2003-04-15 2011-10-01 Sankyo Co Medicament for treatment of intraocular angiopoietic disease
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20090042962A1 (en) * 2005-04-21 2009-02-12 Santen Pharmaceutical Co., Ltd. Therapeutic Agent for Keratoconjunctival Disorder
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
ES2558629T3 (es) * 2008-12-29 2016-02-05 Trevena, Inc. Efectores de beta-arrestina y composiciones y métodos de uso de los mismos
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
AU2015213777A1 (en) 2014-02-07 2016-09-22 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors
CN105188250A (zh) * 2015-09-09 2015-12-23 上海联影医疗科技有限公司 靶组件以及具有该靶组件的直线加速器
CN105244434B (zh) * 2015-10-13 2017-10-10 北京科技大学 一种C掺杂ZnO热电材料的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430709A3 (en) * 1989-12-01 1992-02-12 Glaxo Group Limited Benzthiophen derivatives
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
MX9603259A (es) 1997-03-29
EP0743852B1 (en) 2005-07-27
ES2243933T3 (es) 2005-12-01
JPH09508641A (ja) 1997-09-02
ATE300287T1 (de) 2005-08-15
WO1995021609A1 (en) 1995-08-17
ZA95958B (en) 1995-08-08
DK0743852T3 (da) 2005-10-17
CN1140409A (zh) 1997-01-15
CY2567B1 (en) 2008-07-02
NO963064D0 (no) 1996-07-23
EP0743852A1 (en) 1996-11-27
IL112520A0 (en) 1995-05-26
FI963083A (fi) 1996-08-07
US5889020A (en) 1999-03-30
CA2181461A1 (en) 1995-08-17
FI963083A0 (fi) 1996-08-05
DE69534339D1 (de) 2005-09-01
AU1423795A (en) 1995-08-29
DE69534339T2 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
ATE235470T1 (de) Gastrin- und cck-antagonisten
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
WO1999024051A3 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
BR9809071A (pt) Agentes farmacológicos
DK0711283T3 (da) Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
ATE169019T1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
SE9302218D0 (sv) New use
SE9404438D0 (sv) New process
CA2228572A1 (en) Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi